G1 Therapeutics, Inc. announced that an abstract exploring the long-term impact of trilaciclib on survival outcomes in patients with metastatic triple negative breast cancer from the Company’s Phase 2 trial will be presented in a poster session during the upcoming 2023 San Antonio Breast Cancer Symposium, held December 5th through 9th in San Antonio, TX.
